Opinion|Videos|March 28, 2025
Balancing Approved Therapies and Patient Preference in Parkinson Disease
Author(s)Daniel E. Kremens, MD, JD
An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.
Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins.
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient
3
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
4
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
5